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Abstract 
Background: Empagliflozin has been shown to reduce cardiovascular mortality, but the underlying pathogenetic 
mechanisms are poorly understood. It was previously demonstrated that empagliflozin improved arterial stiffness.
Methods: Our analysis comprising 58 patients with type 2 diabetes mellitus identifies factors triggering the improve-
ment of arterial stiffness. All patients participated in an investigator-initiated, prospective, double-blind, randomized, 
placebo-controlled, interventional clinical trial (http://www.Clini calTr ials.gov: NCT02471963, registered 15th June 
2015, retrospectively registered) and received either 6-weeks treatment with 25 mg empagliflozin orally once daily or 
placebo (crossover). Central systolic pressure and central pulse pressure were recorded by the SphygmoCor System 
(AtCor Medical). Now, we investigated the impact of parameters of glucose metabolism, volume status, sympathetic 
activation, lipids, uric acid, blood pressure and inflammation on vascular parameters of arterial stiffness using multi-
variate regression analysis.
Results: As previously reported, therapy with empagliflozin improved arterial stiffness as indicated by reduced 
central systolic blood pressure (113.6 ± 12.1 vs 118.6 ± 12.9 mmHg, p < 0.001), central pulse pressure (39.1 ± 10.2 vs 
41.9 ± 10.7 mmHg, p = 0.027) forward (27.1 ± 5.69 vs 28.7 ± 6.23 mmHg, p = 0.031) as well as reflected wave ampli-
tude (18.9 ± 5.98 vs 20.3 ± 5.97 mmHg, p = 0.045) compared to placebo. The multivariate regression analysis included 
age, sex and change between empagliflozin and placebo therapy of the following parameters: HbA1c, copeptin, 
hematocrit, heart rate, LDL-cholesterol, uric acid, systolic 24-h ambulatory blood pressure and high sensitive CRP 
(hsCRP). Besides the influence of age (beta = − 0.259, p = 0.054), sex (beta = 0.292, p = 0.040) and change in systolic 
24-h ambulatory blood pressure (beta = 0.364, p = 0.019), the change of hsCRP (beta = 0.305, p = 0.033) emerged as a 
significant determinant of the empagliflozin induced reduction in arterial stiffness (placebo corrected). When replac-
ing HbA1c with fasting plasma glucose in the multivariate regression analysis, a similar effect of the change in hsCRP 
(beta = 0.347, p = 0.017) on arterial stiffness parameters was found.
Conclusion: Besides age and sex, change in systolic 24-h ambulatory blood pressure and change in hsCRP were 
determinants of the empagliflozin induced improvement of vascular parameters of arterial stiffness, whereas param-
eters of change in glucose metabolism and volume status had no significant influence. Our analysis suggests that 
empagliflozin exerts, at least to some extent, its beneficial vascular effects via anti-inflammatory mechanisms.
Trial registration http://www.Clini calTr ials.gov: NCT02471963, registered 15th June 2015, retrospectively registered
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Introduction
Treatment of type 2 diabetes should aim at improving vas-
cular structure and function in the micro- and macrocir-
culation besides metabolic control [1]. Arterial stiffness, a 
key parameter of vascular changes, is characterized by an 
increased pulse wave velocity along the arterial tree of both 
the forward and backward (reflected) pulse wave leading to 
increased central systolic blood pressure and elevated cen-
tral pulse pressure [2, 3]. Central systolic blood pressure is 
the integral of various components of arterial stiffness, an 
important surrogate parameter of afterload, and strongly 
linked to future cardiovascular outcome [4, 5]. Likewise, 
central pulse pressure has been shown to be superior in 
the prediction of cardiovascular events compared to meas-
urements of pulse pressure at the brachial level, and there 
is evidence for an association between both forward and 
backward wave amplitudes and increased risk for incident 
cardiovascular disease and all-cause mortality [5–7].
In the EMPA-REG OUTCOME study (Empagliflozin 
Cardiovascular Outcome Event Trial in Type 2 Diabetes 
Mellitus Patients) treatment with the selective sodium-
glucose cotransporter 2 inhibitor (SGLT2-inhibitor) empa-
gliflozin reduced the primary combined cardiovascular end 
point as well as secondary end points of hospitalization due 
to heart failure, cardiovascular morbidity, total mortality 
and renal end points [8]. The underlying pathophysiologic 
mechanisms are currently under intensive discussion, but 
the crucial question about the pivotal mechanism causing 
the reduced cardiovascular death rate and total mortal-
ity still remains to be elucidated. Interestingly, the benefits 
observed in the EMPA-REG OUTCOME study were docu-
mented in a population in whom cardiovascular risk fac-
tors, including blood pressure and dyslipidemia were well 
treated with the use of renin–angiotensin–aldosterone sys-
tem inhibitors, statins and acetylsalicylic acid. The authors 
of the EMPA-REG OUTCOME study mention changes in 
arterial stiffness among others as possible mechanisms [8]. 
Most recently we have shown that empagliflozin improves 
arterial stiffness in a double blind, placebo controlled, 
crossover clinical trial including 71 patients with type 2 
diabetes mellitus [9]. The aim of the current analysis is to 
identify potential determinants for the improvement of 
arterial stiffness observed during empagliflozin therapy.
Methods
Study design
This is a prespecified analysis of patients, who partici-
pated in an investigator initiated prospective, double 
blind, randomized, placebo-controlled, cross-over, inter-
ventional single center study conducted at the Clinical 
Research Center of the Department of Nephrology and 
Hypertension, University of Erlangen-Nuremberg, Ger-
many (http://www.crc-erlan gen.de) (http://www.Clini 
calTr ials.gov: NCT02471963). The principal findings of 
the clinical trial have been previously published [9]. Par-
ticipants were recruited by advertising in local newspa-
pers in the area of Erlangen-Nuremberg, Germany, and 
eligible participants were enrolled consecutively. Writ-
ten informed consent was obtained before study inclu-
sion. The study protocol was approved by the local ethics 
committee (University of Erlangen-Nuremberg), and the 
study was conducted in accordance with the Declaration 
of Helsinki and the principles of good clinical practice 
guidelines.
Analysis of changes in variables
On the basis of evidence from previous studies [10] the 
following mediators involving several mechanistic cat-
egories have been chosen for analysis: Glucose control 
(HbA1c, fasting plasma glucose), volume status (copep-
tin, hematocrit), sympathetic activation (heart rate), 
lipids (LDL-cholesterol), vascular tone (systolic 24-h 
ambulatory blood pressure), inflammation [high sensitive 
CRP (hsCRP)] and other (uric acid).
Study population
Characteristics of the study population have been pre-
viously published [9]. In brief, female and male patients 
aged between 18 and 75 years with diagnosed type 2 dia-
betes mellitus, defined by fasting glucose ≥ 126 mg/dl or 
HbA1c ≥ 6.5% (48 mmol/mol) or on blood glucose low-
ering medication, were included in the study. Estimated 
glomerular filtration rate (eGFR) had to be ≥ 60  ml/
min/1.73  m2. Patients who used insulin, glitazone, 
gliptine or SGLT-2 inhibitor therapy within the past 
3  months and patients with more than one oral blood 
glucose lowering medication were excluded. Patients on 
any antidiabetic agent had at least a 4  weeks wash-out 
phase prior to the baseline examination. Other key exclu-
sion criteria were HbA1c ≥ 10% (86  mmol/mol), fasting 
plasma glucose > 240  mg/dl, any history of stroke, tran-
sient ischemic attack, instable angina pectoris or myo-
cardial infarction within the last 6 months prior to study 
inclusion, uncontrolled hypertension (office blood pres-
sure ≥ 180/110  mmHg), congestive heart failure (CHF) 
NYHA stage III and IV, use of loop diuretics and preg-
nancy. Eight patients from the original study cohort (71 
patients) were excluded because they presented with 
hsCRP values above 5  mg/l. Another five patients from 
the original study cohort showed a clinical infect cor-
relate such as cystitis, vaginal infection, cold or gout. 
Even though these patients did not present with hsCRP 
above 5  mg/dl, they were excluded from our analysis 
based on the clinical investigation. Conventional blood 
pressure and heart rate measurements in the office and 
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during 24-h were carried in standard fashion by validated 
devices.
Treatment
Patients underwent a run-in/wash-out phase of 4 weeks 
if pretreated with any antidiabetic agent, or 2  weeks if 
not pretreated with any antidiabetic agent and after-
wards were randomized to either empagliflozin 25  mg 
orally once daily or placebo. Following 6 weeks of treat-
ment with either of these drugs, the patient underwent 
a wash-out phase of 1  week. Then the patient received 
the other substance for another 6 weeks of intervention 
(cross-over).
Assessment of vascular function and central 
hemodynamics
To derive the central (aortic) arterial waveform, a vali-
dated system (SphygmoCorTM System; AtCor Medical, 
Sydney, Australia) was applied [5, 7, 20] by recording 
radial artery waveforms from the radial artery at the 
wrist, using high-fidelity applanation tonometer (Mil-
lar Instruments, Houston, Tex.) [5, 6, 20]. Correspond-
ing central (aortic) waveforms were then automatically 
generated from the radial artery waveform by a validated 
transfer function [5, 7]. This allows obtainment of the 
following parameters: central systolic pressure, central 
pulse pressure, central augmentation pressure, central 
augmentation index (cAIx), cAIx normalized to a heart 
rate of 75 beats per minute (cAIx@75), pulse pressure 
amplification, as well as forward and backward reflected 
wave amplitude.
Assessment of blood pressure and potential determinants 
of vascular function
Office blood pressure measurement was performed in a 
standardized fashion according to guideline recommen-
dations [4]. During 24-h ambulatory daily-life conditions, 
brachial systolic and diastolic blood pressure, pulse pres-
sure and heart rate were measured by the Mobilograph 
(IEM, Aachen, Germany). The technology has been vali-
dated previously [5, 11, 12].
All blood samples were measured centrally at the 
biochemistry laboratory of the University of Erlangen-
Nuremberg according to established methods. In par-
ticular, hsCRP was measured via particle-reinforced 
nephelometry. Copeptin was analysed by lab MVZ Dr. 
Limbach GbR using Time Resolved Amplified Cryptate 
Emission method. Coefficient of variation of measure-
ments was below 10%.
Statistical methods
Normal distribution of data was confirmed by histogram 
and Kolmogorov–Smirnov test prior to further analysis. 
Data were compared by paired and unpaired t-tests and 
expressed as mean ± standard deviation (SD) in text and 
tables. A two-sided p-value < 0.05 was considered sta-
tistically significant. Bivariate correlation analyses were 
performed using Pearson’s test. Multivariate regression 
analysis was performed including the parameters sex, age 
and change of the following parameters under treatment 
with empagliflozin: HbA1c (model 1), copeptin concen-
tration, hematocrit, 24-h ambulatory heart rate, LDL-
cholesterol, uric acid, 24-h ambulatory blood pressure 
and hsCRP. A second multivariate regression analysis 
model included besides the other previously mentioned 
parameters fasting plasma glucose instead of HbA1c 
(model 2). Vascular stiffness parameters entered our 
model as an independent variable, namely as first change 
in central systolic blood pressure, second change in pulse 
pressure, third change in forward wave amplitude and 
fourth change in reflected wave amplitude. A separate 
multiple regression analysis was performed for each of 
the four independent variables mentioned. Potential col-
linearity between the dependent variables in our model 
has been excluded by calculating correlation coefficients 
between the dependent variables. There is no correlation 
between change in systolic 24-h ambulatory blood pres-
sure and sex (r = − 0.006, p = 0.967), age (r = − 0.008, 
p = 0.955) and change of the following parameters: uric 
acid (r = 0.104, p = 0.443), hsCRP (r = − 0.027, p = 0.844), 
LDL-cholesterol (r = − 0.204, p = 0.129), fasting plasma 
glucose (r = 0.165, p = 0.220), hematocrit (r = 0.93, 
p = 0.490) and copeptin (r = − 0.074, p = 0.591). All anal-
yses were performed using IBM SPSS Statistics 22 (SPSS 
Inc, Chicago, IL/USA).
Results
Study population
Characteristics of the study cohort have been previously 
published [9]. In brief, the study cohort comprised 58 
patients with type 2 diabetes mellitus (all Caucasians, 
59% male) with mean age of 62 ± 7 years, HbA1c level of 
6.69 ± 0.8% (50 ± 8.7  mmol/mol), office blood pressure 
128 ± 13/78 ± 7.2  mmHg, 24-h ambulatory blood pres-
sure 129 ± 10/79 ± 6.3  mmHg, body weight 87.7  kg and 
body mass index of 29.5 ± 3.9 kg/m2. None of the patients 
were on any antidiabetic medication (85% were on met-
formin prior to study inclusion), whereas 50 patients 
received antihypertensive medications at baseline (84% 
received an angiotensin receptor blocker or an ACE-
inhibitor), without any changes in medication through-
out the study period.
Influence of empagliflozin therapy
Consistent with our previous results [9], after ther-
apy with empagliflozin there was a decrease in HbA1c 
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(p < 0.001), fasting plasma glucose (p < 0.001), body 
weight (p < 0.001), brachial office blood pressure 
(p < 0.001/p = 0.002), 24-h ambulatory blood pressure 
(p = 0.021/p = 0.007), central systolic blood pressure 
(p < 0.001) and central pulse pressure (p = 0.027) forward 
(p = 0.031) and backward (reflected) wave amplitude 
(p = 0.045) compared to placebo (Table 1).
Further analysis now included volume parameters 
such as copeptin and hematocrit, parameters of glucose 
metabolism such as HbA1c and fasting plasma glucose, 
hsCRP as parameter of inflammation, LDL-cholesterol, 
uric acid, and heart rate as parameter of sympathetic 
activation (Table  1). Copepetin levels (p < 0.001) and 
hematocrit (p = 0.004) were higher in patients treated 
with empagliflozin compared to placebo (Table  1). Uric 
acid (p < 0.001) was lower in patients treated with empa-
gliflozin compared to placebo (Table  1). No difference 
between empagliflozin and placebo therapy was observed 
in heart rate (p = 0.513), total cholesterol (p = 0.413) as 
well as HDL- (p = 0.219) and LDL-cholesterol (p = 0.425) 
and hsCRP (p = 0.458). Estimated glomerular filtration 
rate (p < 0.001) was significantly lower after treatment 
with empagliflozin compared to placebo (Table 1).
Multivariate regression analysis
Model 1 of the multiple regression analysis identified 
change in systolic 24-h ambulatory blood pressure as the 
only significant determinant of change in central systolic 
blood pressure after therapy with empagliflozin (Tables 2 
and 3). Besides change in hematocrit, change in 24-h 
ambulatory blood pressure was also a determinant of 
change in forward wave amplitude. Interestingly, change 
in hsCRP and change in systolic 24-h ambulatory blood 
pressure emerged besides age as significant determinants 
of change in central pulse pressure (Table 2). Besides the 
influence of change in systolic 24-h ambulatory blood 
pressure, there was a trend towards a significant influ-
ence of change in hsCRP on change in reflected wave 
amplitude (Table 3).
In model 2 of the multivariate regression analy-
sis change in systolic 24-h ambulatory blood pressure 
emerged as the only significant determinant of change 
in central systolic blood pressure, and besides hemato-
crit as the only determinant of change in forward wave 
amplitude after therapy with empagliflozin (Tables  2 
and 3). Again, change in hsCRP and change in systolic 
24-h ambulatory blood pressure emerged besides age as 
Table 1 Effect of empagliflozin on metabolic parameters
Data are given as mean ± SD
OBP office blood pressure, 24-h ABP 24 h ambulatory blood pressure, PP pulse pressure, FWA forward wave amplitude, BWA backward wave amplitude, HR heart rate, 
LDL low density lipid, HDL high density lipid, eGFR estimated glomerular filtration rate (calculated from serum creatinine using CKD-EPI formula), hsCRP high sensitive 
C-reactive protein
Parameter Baseline EMPA Placebo EMPA vs baseline Placebo vs 
baseline
Verum vs placebo
HbA1c (%) 6.69 ± 0.82 6.64 ± 0.76 6.89 ± 1.03 < 0.001 < 0.001 < 0.001
HbA1c (mmol/mol) 50 ± 9.0 49 ± 8.3 52 ± 11.3 < 0.001 < 0.001 < 0.001
Fasting plasma glucose (mg/dl) 136.5 ± 31.4 115.1 ± 19.7 139.2 ± 40.7 < 0.001 0.384 < 0.001
Body weight (kg) 87.7 ± 12.9 86.6 ± 12.6 87.6 ± 12.9 < 0.001 0.858 < 0.001
Systolic OBP (mmHg) 128 ± 13.4 122 ± 11.4 128 ± 12.7 < 0.001 0.878 < 0.001
Diastolic OBP (mmHg) 77.7 ± 7.2 75 ± 6.7 78 ± 7.9 < 0.001 0.999 0.002
Systolic 24-h ABP (mmHg) 129 ± 10.4 127 ± 9.8 129 ± 9.7 0.053 0.868 0.021
Diastolic 24-h ABP (mmHg) 79.2 ± 6.3 77.7 ± 6.9 80 ± 7.0 0.041 0.624 0.007
Central systolic BP (mmHg) 120.3 ± 12.8 113.6 ± 12.1 118.6 ± 12.9 < 0.001 0.237 < 0.001
Central PP (mmHg) 43.3 ± 11.5 39.1 ± 10.2 41.9 ± 10.7 < 0.001 0.248 0.027
FWA (mmHg) 28.9 ± 6.24 27.0 ± 5.64 28.7 ± 6.23 0.002 0.553 0.031
BWA (mmHg) 21.2 ± 6.48 18.9 ± 5.98 20.4 ± 6.01 < 0.001 0.248 0.045
Copeptin (pmol/l) 5.65 ± 4.12 6.81 ± 4.13 5.06 ± 2.83 0.001 0.211 < 0.001
Hematocrit (%) 41.5 ± 2.78 43.0 ± 2.75 42.2 ± 2.73 < 0.001 0.032 0.004
HR (bpm) 72.5 ± 9.17 71.8 ± 9.18 72.2 ± 10.3 0.439 0.787 0.577
Cholesterol (mg/dl) 178.1 ± 35.3 182.5 ± 39.0 180.3 ± 36.9 0.077 0.325 0.413
LDL-cholesterol (mg/dl) 88.0 ± 24.2 92.9 ± 27.4 91.2 ± 24.3 0.016 0.061 0.425
HDL-cholesterol (mg/dl) 52.2 ± 11.3 54.5 ± 12.9 53.4 ± 11.8 < 0.002 0.086 0.219
Uric acid (mg/dl) 6.05 ± 1.26 4.85 ± 1.27 5.89 ± 1.23 < 0.001 0.061 < 0.001
eGFR (ml/min/1.73 m2) 92.7 ± 6.98 91.2 ± 7.42 92.5 ± 7.01 < 0.001 0.535 < 0.001
hsCRP (mg/l) 2.10 ± 1.72 1.99 ± 1.19 1.88 ± 1.32 0.583 0.283 0.458
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significant determinant of change in central pulse pres-
sure and besides sex as significant determinant of change 
in backward (reflected) wave amplitude (Tables 2 and 3).
Correlations
There was a relation between central pulse pressure 
(r = 0.309, p = 0.018, Fig.  1a) as well as central reflected 
wave amplitude (r = 0.309, p = 0.020, Fig. 1b) and hsCRP 
6  weeks after treatment with empagliflozin. No rela-
tion was found between central systolic blood pressure 
(r = 0.165, p = 0.217) as well as central forward wave 
amplitude (r = 0.183, p = 0.177) and hsCRP after empa-
gliflozin treatment. No relation was present between pla-
cebo corrected changes in hsCRP and changes in central 
systolic blood pressure as well as changes in central pulse 
pressure, central forward and reflected wave amplitude 
(data not shown).
Sub analysis of total study population
Dividing the study population according to median of 
age, baseline HbA1c, copeptin, 24-h ambulatory heart 
rate, LDL-cholesterol, uric acid, systolic 24-h ambulatory 
blood pressure and hsCRP at baseline did also not reveal 
any difference in change in central systolic blood pres-
sure (Table 4), change in central pulse pressure (Table 5), 
change in forward (Table 6) and change in reflected wave 
amplitude (Table  7) after treatment with empagliflozin 
between the groups. However, when separating the study 
population according to median of baseline copeptin, 
patients above median showed a greater change in cen-
tral systolic blood pressure (Table  4) and central pulse 
pressure (Table  5), suggesting that greater intravascular 
volume contraction was positively influencing some of 
the stiffness parameters.
Discussion
The SGLT-2 inhibitor empagliflozin recently emerged 
as a novel cardioprotective and nephroprotective treat-
ment strategy [8, 13–15]. Empagliflozin reduced central 
systolic blood pressure and central pulse pressure, both 
important surrogate parameters strongly linked to future 
cardiovascular outcome which may serve to explain the 
reduction in cardiovascular mortality observed in the 
EMPA-REG OUTCOME study to some extent. Consist-
ently, empagliflozin induced reduction of arterial stiff-
ness has been previously reported in a post hoc analysis 
of data from five clinical trials [16]. We showed now that 
besides age and sex, change in systolic 24-h ambulatory 
blood pressure and change in hs CRP were determinants 
of the empagliflozin induced improvement of arterial 
stiffness parameters, whereas change in glucose metabo-
lism and volume status were not related to the improve-
ment of arterial stiffness following empagliflozin therapy.
Central systolic blood pressure is primarily determined 
by arterial stiffness of large arteries and was found to be 
independently associated with cardiovascular morbidity 
and mortality [3, 4, 17]. Increasing arterial stiffness leads 
to increased pulse wave propagation along the artery tree 
resulting in elevated carotid femoral pulse wave veloc-
ity and finally augmented central systolic blood pressure 
[17–20]. Elevated aortic stiffness increases the hemody-
namic load on the left ventricle and thereby represents 
one of the pre-dominant pathogenetic mechanisms lead-
ing to the development of heart failure. In the EMPA-
REG OUTCOME study empagliflozin was given on top 
of a concomitant cardioprotective therapy. The observed 
reduced heart failure hospitalization and reduced cardio-
vascular death rate was possibly caused by a reduction in 
central systolic blood pressure [8]. In our clinical study 
arterial stiffness was reduced independent of changes in 
metabolic conditions but dependent on systolic blood 
pressure [9]. Therefore our results strengthen the role 
of empagliflozin as predominantly vasoprotective agent. 
Interestingly, clinical data revealed that the dapagliflozin 
mediated improvement of arterial stiffness, endothelial 
function and renal resistive index was independent of 
changes in blood pressure, suggesting a direct beneficial 
effect on the vasculature, possibly mediated by oxida-
tive stress reduction [21]. Furthermore, clinical data also 
showed a reduction in arterial stiffness after therapy with 
canagliflozin [22]. Tofogliflozin has also been found to 
ameliorate arterial stiffness, which was associated with 
an improvement of liver function [23].
It is a matter of current discussion whether the reduc-
tion in mortality seen under therapy with empagliflo-
zin is attributed to glycemic independent effects rather 
than glycemic control. Indeed, administration of a 
SGLT2 inhibitor on top of standard glucose lowering 
therapy modestly reduced (~ 0.4%) glycated hemoglobin 
plasma levels and was associated with small decreases in 
body weight, plasma insulin and blood pressure [8, 24]. 
However, it is unlikely that the small changes in these 
parameters can explain the large beneficial actions of 
SGLT2 inhibitors [25]. In  vivo preclinical studies have 
shown decreased oxidative stress, reduced inflammatory 
cytokines, lowered ionic dyshomeostasis and decreased 
vascular and mitochondrial dysfunction after SGLT2 
inhibitor administration [25–31]. Other animal studies 
revealed further glycemic independent effects such as 
the maintenance of cardiac cell viability and ATP con-
tent following hypoxia/reoxygenation in cardiomyocytes 
and endothelial cells [25]. In the rat model empagliflozin 
causes direct pleiotropic effects on the myocardium by 
improving diastolic stiffness and hence diastolic function 
[32], but it is unclear whether these effects are also pre-
sent in humans, since SGLT2 is not expressed in human 
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Fig. 1 a Relation between hsCRP after 6 weeks treatment with empagliflozin and central pulse pressure after treatment with empagliflozin 
(r = 0.309, p = 0.018). b Relation between hsCRP after 6 weeks treatment with empagliflozin and reflected wave amplitude after treatment with 
empagliflozin (r = 0.309, p = 0.020)
Table 4 Mean change in  central systolic blood pressure (mmHg) after  EMPA therapy separated according to  median 
of different variables
Data are given as mean ± SD
hsCRP high sensitive C-reactive protein, LDL-cholesterol low density lipid cholesterol, heart rate 24 h ambulatory heart rate, systolic BP systolic 24-h ambulatory blood 
pressure
Variable Age HbA1c Copeptin Heart rate LDL-cholesterol Uric acid Systolic BP hsCRP
≥ median − 6.23 ± 11.2 − 6.46 ± 11.1 − 8.94 ± 10.2 − 4.49 ± 9.89 − 5.50 ± 12.1 − 6.21 ± 9.54 − 5.13 ± 10.6 − 4.21 ± 10.3
< median − 3.76 ± 9.83 − 3.61 ± 9.97 − 1.78 ± 9.83 − 5.48 ± 11.3 − 4.51 ± 9.06 − 3.76 ± 11.45 − 4.88 ± 10.7 − 5.77 ± 10.9
p-value 0.378 0.308 0.009 0.724 0.724 0.378 0.928 0.576
Table 5 Mean change in central pulse pressure (mmHg) after EMPA therapy separated according to median of different 
variables
Data are given as mean ± SD
hsCRP high sensitive C-reactive protein, LDL-cholesterol low density lipid cholesterol, heart rate 24-h ambulatory heart rate, systolic BP systolic 24-h ambulatory blood 
pressure
Variable Age HbA1c Copeptin Heart rate LDL-cholesterol Uric acid Systolic BP hsCRP
≥ median − 4.66 ± 8.87 − 4.77 ± 9.04 − 5.54 ± 8.25 − 1.03 ± 9.37 − 1.95 ± 11.9 − 3.978 ± 9.39 − 2.65 ± 9.46 − 1.82 ± 8.11
< median − 0.83 ± 9.27 − 0.84 ± 9.08 − 0.47 ± 9.43 − 4.45 ± 8.86 − 3.48 ± 5.82 − 1.51 ± 8.99 − 2.81 ± 9.13 − 3.67 ± 10.2
p-value 0.114 0.105 0.033 0.160 0.533 0.311 0.949 0.449
Table 6 Mean change in  forward wave amplitude (mmHg) after  EMPA therapy separated according to  median 
of different variables at baseline
Data are given as mean ± SD
hsCRP high sensitive C-reactive protein, LDL-cholesterol low density lipid cholesterol, heart rate 24-h ambulatory heart rate, systolic BP systolic 24-h ambulatory blood 
pressure
Variable Age HbA1c Copeptin Heart rate LDL-cholesterol Uric acid Systolic BP hsCRP
≥ median − 1.98 ± 5.31 − 2.14 ± 5.46 − 2.56 ± 5.60 − 1.86 ± 4.94 − 1.95 ± 6.47 − 2.23 ± 5.33 − 0.76 ± 5.10 − 1.31 ± 4.99
< median − 1.19 ± 5.26 − 1.03 ± 5.07 − 0.81 ± 4.90 − 1.29 ± 5.65 − 1.27 ± 4.01 − 1.03 ± 5.21 − 2.30 ± 5.36 − 1.86 ± 5.58
p-value 0.585 0.442 0.225 0.692 0.638 0.406 0.287 0.708
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cardiac tissue [30]. However, there is also evidence that 
glycemic control by empagliflozin directly decreases 
macro- and micro-vascular stiffness [33]. In the mouse 
model hyperglycemia suppressed the anti-fibrotic fac-
tor “reversion inducing cysteine rich protein with Kazal 
motifs” (RECK) in the kidney, which causes an increase of 
renal periarterial and interstitial fibrosis [33]. This leads 
to an increase in renal vascular stiffness followed by an 
increase of aortic stiffness. Empagliflozin has been shown 
to ameliorate kidney injury in type 2 diabetic female mice 
by promoting glycosuria, and possibly by reducing sys-
temic and renal artery stiffness, and reversing RECK sup-
pression [33].
Our study suggests that hsCRP might be a determinant 
of the empagliflozin induced improvement of central 
pulse pressure and reflected wave amplitude. It has been 
previously shown in rat models that therapy with empa-
gliflozin reduces inflammatory processes in the diabetic 
kidney via suppression of the advanced glycation end 
product receptor axis [26, 34]. In a high-fat-diet-induced 
obese mouse model empagliflozin reduced plasma TNF 
alpha levels and attenuated obesity-related chronic 
inflammation [35]. We now identified a relation between 
reduction in hsCRP and reduction of arterial stiffness in 
patients with early stage of type 2 diabetes mellitus. Inter-
estingly, therapy with dapagliflozin partially reversed 
the formation of atherosclerosis via anti-inflammatory 
pathways in mice [36] and there is clinical evidence that 
16  weeks of therapy with dapagliflozin reduced urine 
8-hydroxy-2′-deoxyguanosine, a biomarker of oxidative 
stress  [37]. Further clinical studies are needed to evalu-
ate the impact of SGLT2 inhibitors on diabetes induced 
inflammatory processes. Especially the measurement 
of empagliflozin associated changes in oxidative stress 
parameters would we very interesting to better under-
stand the influence of the drug on vascular function and 
stiffness.
The increase in copeptin levels and hematocrit meas-
ured after empagliflozin therapy compared to baseline 
mirrors volume depletion due to osmotic diuresis caused 
by glucosuria and natriuresis. It has been previously 
shown that SGLT2 inhibitors have a modest osmotic 
diuretic and natriuretic effect, which can reduce extra-
cellular volume, blood pressure and body weight [38]. 
In the current analysis we did not observe a signal that 
volume depletion account for the improvement in arte-
rial stiffness following empagliflozin treatment. However, 
a mediation analysis of the EMPA-REG OUTCOME trial 
identified hematocrit to be the variable with the larg-
est impact on the hazard ratio for cardiovascular death 
[10]. As many participants in the EMPA-REG OUT-
COME trial likely have unrecognized left ventricular 
dysfunction it was concluded that a key contributor to 
the reduction in cardiovascular death with empagliflo-
zin was probably the change in renal sodium and glucose 
handling with resultant reduction in cardiac preload and 
ventricular stress [10]. Afterload reductions may have 
occurred through blood pressure and arterial stiffness 
lowering, thereby improving sub endocardial blood flow 
and reducing the risk of cardiac decompensation [10, 
30]. The patients included in our clinical trial were in the 
early state of diabetes without evident end-organ dam-
age. This might explain why we did not see an impact of 
volume status in our analysis. However, we still found an 
increase of hematocrit and copeptin in our study cohort. 
Previous studies identified complementary increased 
erythropoiesis as other potential mechanism to the 
hemodynamic changes reflected by an increase in hem-
atocrit [39]. Additionally it has been shown that blood 
viscosity and shear stress in the aortic arteries increased 
after 3  month empagliflozin therapy in type 2 diabetic 
patients [40]. However, the extent to which this mecha-
nism contributes to the cardiovascular benefits observed 
with empagliflozin is unclear [10]. Additionally it has to 
be mentioned that the volume parameters hematocrit 
and copeptin have known background variation. Fur-
ther research based on biomarkers with less background 
variation and larger study cohorts is needed to evaluate 
the effect of volume status on the empagliflozin induced 
reduction of arterial stiffness.
In our study population there was a small, but signifi-
cant increase in LDL- and HDL-cholesterol, which has 
also been previously described in the EMPA-REG-OUT-
COME study [8]. This effect can be pathophysiologically 
Table 7 Mean change in  reflected wave amplitude (mmHg) after  EMPA therapy separated according to  median 
of different variables
Data are given as mean ± SD
hsCRP high sensitive C-reactive protein, LDL-cholesterol low density lipid cholesterol, heart rate 24-h ambulatory heart rate, systolic BP systolic 24-h ambulatory blood 
pressure
Variable Age HbA1c Copeptin Heart rate LDL-cholesterol Uric acid Systolic BP hsCRP
≥ median − 1.82 ± 4.93 − 2.25 ± 5.05 − 2.56 ± 4.54 − 0.88 ± 4.74 − 0.43 ± 5.86 − 1.94 ± 4.45 − 1.44 ± 5.18 − 0.26 ± 4.54
< median − 0.83 ± 4.64 − 0.41 ± 4.36 − 0.35 ± 4.78 − 1.82 ± 4.84 − 2.11 ± 3.49 − 0.79 ± 5.03 − 1.24 ± 4.46 − 2.39 ± 4.83
p-value 0.449 0.159 0.091 0.471 0.199 0.382 0.877 0.101
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explained, since reduced insulin levels caused by SGLT2 
inhibition are known to trigger lipolysis by switching 
energy metabolism from carbohydrate to lipid utiliza-
tion [38]. It has been hypothesized that this switch from 
carbohydrate to lipid utilization among others, such 
as reduced ketone clearance and stimulation of gluca-
gon secretion, might explain the elevated risk of dia-
betic ketoacidosis under therapy with SGLT2 inhibitors. 
Diabetic ketoacidosis has been reported with the three 
available SGLT2 inhibitors [41]. However results from 
randomized controlled trials show that it is a rare event 
in patients with type 2 diabetes mellitus [41]. Interest-
ingly, it was shown in animal studies, that empagliflozin 
reduces intestinal cholesterol absorption, which in turn 
promotes LDL- and macrophage-derived cholesterol 
fecal excretion [42]. We demonstrated in our study pop-
ulation that changes in LDL-levels under therapy with 
empagliflozin are not related to the changes in arterial 
stiffness.
It has been recently shown in a post hoc analysis of 
the EMPA-REG OUTCOME trial that changes in uric 
acid mediated 24.6% of the effect of empagliflozin versus 
placebo on the reduction in risk of cardiovascular death 
[10]. We therefore integrated uric acid in our analysis and 
found a significant decrease after 6  weeks therapy with 
empagliflozin compared to placebo. Nevertheless, we 
could not show any relation between changes in uric acid 
and changes in arterial stiffness.
Limitations
One major selection bias limits the generalization of the 
study: only patients with normal kidney function were 
included and most patients with cardiovascular disease 
or advanced diabetes were excluded. Therefore the inves-
tigated relations only apply to patients in the early stage 
of diabetes without relevant end-organ damage.
The markers for volume status (copeptin and hema-
tocrit) as well as sympathetic activation (heart rate) are 
only crude biomarkers with a lot of background variation, 
especially in a small study population like this. Therefore, 
based on the results of this study, it cannot be concluded 
that volume status and sympathetic activation are not 
important mediators in the effects of SGLT-2 inhibitors.
Of course, though prespecified, such an analysis of 
potential outcome determinants can only be the first 
step in the identification of factors explaining the vaso-
protective potential of empagliflozin. We used placebo 
corrected changes in our analysis, since the differences 
between empagliflozin and placebo induced changes 
observed in the same patient entered our multiple 
regression analysis. The correlations between markers 
of vascular stiffness and hsCRP were statistically signif-
icant, but very weak and therefore clinical significance 
is unsure. Nevertheless, the signal that inflammation 
might influence empagliflozin induced reduction of 
arterial stiffness was present in two different statisti-
cal methods (multiple regression analysis and cor-
relation) and might therefore be an interesting target 
for future investigations. Further clinical trials with 
detailed parameters of volume status, inflammation 
and sympathetic activation are needed to better under-
stand the precise mechanism of empagliflozin-induced 
vasoprotection.
Conclusion
Besides age and sex, change in systolic 24-h ambulatory 
blood pressure and change in hsCRP were determinants 
of the empagliflozin induced improvement of vascular 
parameters of arterial stiffness, whereas parameters of 
change in glucose metabolism, lipid metabolism, uric 
acid, sympathetic activation as assessed by heart rate 
and volume status had no significant influence. Our 
analysis found a signal that empagliflozin may exert, at 
least to some extent, its beneficial vascular effects via 
anti-inflammatory mechanisms.
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